Discovery rx vct 64 pet

Each participant underwent a PET examination the day after MRI examination. FDG scans were acquired on a Discovery RX VCT 64 PET-CT device (GE Healthcare) with a resolution of 3.76 × 3.76 × 4.9 mm³ FWHM (axial field of view = 157 mm). Forty-seven planes were obtained with septa out (3D acquisition), with a voxel size of 2.7 × 2.7 × 3.27 mm³. A CT transmission scan was performed for attenuation correction before PET acquisition. Participants were fasted for at least 6 h before scanning. After a 30-min resting period in a quiet and dark environment, ~180 MBq of FDG were intravenously injected as a bolus. A 10-min PET acquisition scan began 50 min after injection. During data acquisition, head motion was continuously monitored with laser beams projected onto ink marks drawn on the forehead, which also served to make any necessary corrections.

Both ¹⁸F-fluorodeoxyglucose (FDG)—and florbetapir-PET scans were acquired on a Discovery RX VCT 64 PET-CT device (GE Healthcare) with a resolution of 3.76 × 3.76 × 4.9 mm (field of view = 157 mm). Forty-seven planes were obtained with a voxel size of 2.7 × 2.7 × 3.27 mm. A transmission scan was performed for attenuation correction before the PET acquisition. For FDG-PET, participants, fasted for at least 6 hours before scanning, were at rest in a quiet and dark room before tracer injection. Approximately 180 MBq of FDG was injected intravenously 50 mins before a 10-min acquisition scan. For the amyloid-PET scan, ≈ 4 MBq/kg of florbetapir was injected intravenously 50 mins before a 20-min acquisition scan.